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Prostaglandins in macula densa function. Cyclooxygenase
(COX)-2 mRNA and immunoreactive protein localize to the
macula densa and adjacent cortical thick ascending limb in renal
cortex, and chronic NaCl restriction increases expression of this
enzyme. These findings suggest an integral role for eicosanoids
generated by macula densa-associated COX-2 in mediating renin
release. As selective inhibitors of COX-2 become available, it will
be important to assess their effects on the renin-angiotensin
system and glomerular hemodynamics.
Prostaglandins (PGs) are important physiological modu-
lators of vascular tone and salt and water homeostasis in
the mammalian kidney. In addition to their well-docu-
mented modulation of glomerular hemodynamics and dis-
tal nephron function, numerous studies suggest a role for
PGs in regulation of renin production. Intrarenal arachi-
donic acid infusion stimulates renin release, and cyclooxy-
genase (COX) inhibitors suppress plasma renin [1–3].
Prostacyclin generated by the afferent arteriole mediates
renin release in response to alterations in intrarenal vascu-
lar tone [4]. In addition, PGs may be mediators of macula
densa (MD)-mediated renin release [5, 6]. Ito et al have
found that in isolated afferent arterioles without an asso-
ciated MD, renin release increases in response to prosta-
cyclin, but not prostaglandin E2 (PGE2). However, with the
MD attached, PGE2 increases renin release, even in the
presence of a prostacyclin synthase inhibitor [7], and more
recent studies using an isolated perfused juxtaglomerular
apparatus preparation have confirmed that an intact COX
pathway is necessary for stimulation of renin release medi-
ated by MD sensing of decreases in luminal NaCl [8].
The source of PGs in the MD-mediated regulation of
renin secretion is still under investigation. One suggestion
has been that primarily the extraglomerular mesangial cells
sense altered interstitial ion concentrations. Studies in
cultured mesangial cells have documented the presence of
a Ca21-activated Cl2 conductance and have demonstrated
that decreased ambient [Cl2] attenuates the responsiveness
of mesangial cells to vasoactive agonists such as angiotensin
II and vasopressin [9] and increases PG [10] and nitric
oxide production [11]. It is thus possible that the extraglo-
merular mesangium may respond to decreased Cl2 reab-
sorption by increasing PG production to stimulate renin
release. Alternatively, recent studies have suggested that
the thick ascending limb (TALH) and MD may be a source
of PGs [12].
Prostaglandin H2 (PGH2) is a common precursor for all
prostanoids, and its production from arachidonic acid is
regulated by the enzyme PG G2/H2 synthase (COX) [13].
There are two separate gene products with COX activity:
COX-1 and COX-2. Although of similar size (about 73
kDa) and with similar enzymatic activities, the isoforms
share only about 66% homology in the amino acid se-
quence. The gene for COX-1, the constitutive isoform,
encodes a 2.7–2.9 kb transcript [14], whereas the gene for
COX-2, the inducible isoform, encodes a 4.2–4.5 kb tran-
script [15–19].
In the kidney, immunoreactive COX-1 is found in high-
est concentrations in mesangial cells, arteriolar endothelial
cells, parietal epithelial cells of Bowman’s capsule, and the
collecting duct and medullary interstitial cells. No immu-
noreactive COX-1 is found in Henle’s loop or MD [20].
COX-2 mRNA was first detected in phorbol ester-
treated Swiss 3T3 cells, and its expression has been shown
subsequently to increase in a variety of cultured epithelial,
mesenchymal, and endothelial cells in response to serum,
growth factors, and inflammatory stimuli [16–19]. COX-2 is
the steroid-sensitive isoform of COX, because glucocorti-
coids decrease COX-2 expression by both transcriptional
and posttranscriptional mechanisms [17, 21]. COX-2 ex-
pression in the kidney increases after systemic administra-
tion of lipopolysaccharide [22]. We have also shown local-
ized expression in the developing and adult kidney that is
regulated by noninflammatory stimuli. Using a cDNA
probe specific for COX-2, we determined constitutive
expression of COX-2 mRNA in normal rat kidney. Immu-
noblotting of microsomes from rat kidney cortex and
papilla with an antiserum specific for COX-2 revealed
immunoreactive protein with a molecular weight of about
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73 kDa in both locations, with greater relative abundance in
papilla. In situ hybridization revealed a restricted distribu-
tion of COX-2 mRNA. In the cortex, it was localized to
cells of the cortical TALH (cTALH) in the region of the
MD. Immunohistochemical studies confirmed that a re-
stricted subset of cells in the outercortex and midcortex
expressed COX-2. These cells were identified as the epi-
thelial cells of the MD and the adjacent cTALH. The
immunoreactivity of stained cells was intense, but only one
(and rarely two) COX-2—positive cell was observed per
site. The majority of identified glomeruli sectioned through
the juxtaglomerular apparatus had no COX-2—positive
cells in the MD. In the papilla, medullary interstitial cells
were COX-2 positive, with the greatest incidence of immu-
noreactivity at the papillary tip. No COX-2 immunoreac-
tivity was detected in arterioles, glomeruli, or cortical or
medullary collecting ducts [12].
To determine whether alterations in volume status alter
cortical COX-2 expression, additional rats were volume
expanded by administering 1% NaCl in drinking water or
volume contracted by placing them on a low-sodium diet.
The number of cells displaying immunoreactive COX-2 in
the cortex did decrease in the volume-expanded animals,
but the baseline was so low that statistical significance was
not reached. In contrast, chronic dietary salt depletion
increased cortical COX-2 immunoreactivity significantly
from 0.86 6 0.08 (N 5 3) to 2.52 6 0.43 (N 5 4) cell
clusters of COX-2 immunoreactivity/mm2 cortex (P ,
0.025). Similarly, the percentage of glomeruli with an
associated COX-2—immunoreactive MD increased from
5 6 1.2 to 16.1 6 3.3% (P , 0.05). In addition to increased
frequency of sites with COX-2—positive cells, more cells of
each MD and associated TALH were positive in the
cortices of low-salt animals. The number of individual
COX-2 immunoreactive cells increased from 0.95 to 4.99
cells/mm2 cortex, and the total area of the COX-2 immu-
noreactive cells in cortex increased from 34 to 226 mm2/
mm2.
PGE2 inhibits net Cl
2 reabsorption in the (non-MD)
cells of the TALH [23]. Locally produced PGs may thus
function as autacoids to inhibit MD transport directly.
Alternatively, PGs may affect signaling by the extracellular
mesangial (Goormaghtigh) cells [11]. Finally, although
epithelial cells of more distal nephron structures produce
predominantly PGE2 [24], the profile of COX products
produced by MD cells is unknown. Although in vitro studies
have not indicated differences between the profile of PGs
produced by purified or recombinant COX-1 and COX-2, it
is possible that MD cells may produce PGI2 and/or other
COX metabolites that directly stimulate renin secretion by
JG cells. Although the metabolites involved or signaling
have still not been determined, a recent study by Harding et
al has demonstrated that administration of a selective
COX-2 inhibitor prevents increases in renal renin mRNA
levels in response to imposition of a low-sodium diet [25].
The mechanisms by which renal cortical COX-2 are
regulated are still under investigation. Given that glucocor-
ticoids inhibit COX-2 expression in inflammatory states, it
is of interest that we have found significant increases in
cTALH COX-2 expression in rats after adrenalectomy [26].
In preliminary studies, we have found also that renal
cortical COX-2 expression in rats on low-salt diets is
increased significantly with concomitant treatment with an
angiotensin converting enzyme inhibitor or angiotensin I
Fig. 2. Cyclooxygenase (COX)-2 expression in kidney homogenates of
rats staged from newborn (P0) to adult. Equivalent amounts of protein
loaded in each lane were separated by gel electrophoresis and transferred
to a membrane for immunochemical identification with COX-2 antibody
(reprinted from [39] with permission from the Journal of Clinical Inves-
tigation).
Fig. 1. Topographic distribution of cyclooxygenase (COX)-2 immunore-
active protein in the kidney. Representative renal sections from control
(A) and low-salt (B) rats. The section profiles and locations of COX-2
positive cells were determined at a resolution of [plusminus] 1 mm
(reprinted from [12] with permission).
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receptor antagonist [27], suggesting negative feedback by
angiotensin II.
It is of interest that COX-2, but not COX-1, is found in
the MD. One possible explanation for this selectivity is that
rapid and transient transcriptional regulation of COX-2
would allow the MD to modulate its PG production to
provide appropriate regulation of the renin/angiotensin
system. The localization of COX-2 to the MD also raises
the possibility that alterations in COX-2 activity may be
involved in renin-dependent hypertension. In this regard, in
a model of renovascular hypertension in rats [28], indo-
methacin decreased systemic blood pressure. Similarly, in
humans with renovascular, but not essential, hypertension,
i.v. aspirin significantly reduced systemic blood pressure
[29].
Evidence suggests that COX metabolites may play im-
portant functional and developmental roles in the fetal
kidney. Mateson et al have found that administration of the
nonspecific COX inhibitor indomethacin to fetal lambs
during the third trimester of gestation increased renal
vascular resistance, decreased fetal renal blood flow, in-
creased urinary sodium and chloride excretion, and de-
creased plasma renin activity, indicating that COX metab-
olites are important for maintenance of fetal renal function
[30]. The incidence of oligohydramnios is reportedly in-
creased in women who chronically consume significant
amounts of aspirin or other COX inhibitors during the
third trimester of pregnancy [31]. Because the fetus is the
source of a significant amount of amniotic fluid, these
studies further suggest an important role for COX metab-
olites in maintenance of fetal renal function.
There is also evidence for a role of COX metabolites in
mediation of normal renal development. Chronic adminis-
tration of indomethacin to pregnant Rhesus monkeys leads
to renal hypoplasia, with kidney size decreased to 15% of
control animals. The observed defect was specific for the
kidney, because in the treated animals, development of the
other organs was not affected, except that the livers were
larger in the treated infants [32]. Human fetal renal malde-
velopment has also been reported with chronic use of COX
inhibitors during pregnancy. The kidneys from these infants
who came to term or died in the early postnatal period were
noted to have few differentiated proximal tubules in the
inner cortex, associated with crowding of the glomeruli.
The outer cortex was more severely affected, with evidence
of poorly differentiated glomeruli, undifferentiated tubule
epithelia, and tubular dilation. In addition, the medullary
pyramids were crowded with small immature tubules [33,
34]. Further evidence for a potential role of COX metab-
olites in nephrogenesis has been provided by studies of
mouse metanephric cultures. Avner et al, studying growth
requirements of embryonic (E) day 13 mouse metanephric
explants grown in the absence of fetal calf serum, have
determined that PGE1 is necessary for maximal growth and
differentiation [35]. In addition to an approximately 33%
decrease in overall cellularity of the metanephric kidney
grown in the absence of PGE1, addition of PGE1 to the
basal media was an essential prerequisite for induction of
metanephric differentiation (measured as development of
epithelial glomeruli formation), and PGE1 by itself was
almost as effective in promoting differentiation as a com-
plete hormonally defined medium (selenium, insulin, trans-
ferrin, thyroxine, and PGE1) [35].
Two recent reports of targeted disruption of murine
COX-2 have also indicated an important developmental
role for this enzyme in renal development [36, 37]. The
kidneys of homozygous (COX-22/2) animals are small,
with a paucity of functional nephrons, undeveloped mes-
enchymal tissue, and immature glomeruli and dysplastic
tubules in the outer cortex. Microcystic lesions are found in
the corticomedullary junction and are accompanied by
hypoplasia or atrophy of the medulla. The average life span
of these mice is 3.5 months, and they die of uremia. The
pathologic presentation appears to be very similar to the
previous descriptions of renal abnormalities in infants of
mothers consuming large quantities of nonsteroidal anti-
inflammatory drugs. No apparent developmental or func-
tional abnormalities have been described in mice with
targeted disruption of COX-1 [38].
We have determined that in normal rat kidney develop-
ment, COX-2 mRNA and immunoreactive protein are
present in the metanephric kidney from day E16 and
COX-2 is apparent in cells of both the collecting ducts
derived from ureteric buds and from the s-shaped bodies
[39]. In late gestation, localized cells with intense COX-2
immunoreactivity were noted in the developing cTALH.
This expression peaked in the third postnatal week and
declined to adult levels by the third postnatal month (Fig.
2). Immunolocalization and in situ hybridization demon-
strated intense COX-2 expression in a subset of cTALH
near the MD in each developing nephron.
The placenta is a rich source of PGs, and in ovine
placenta, COX-2 expression increases in the second half of
pregnancy [40]. Therefore, if PGs or other COX metabo-
lites play an important role in renal development, it is
possible that maternally produced products may be a
contributory source during pregnancy. In the mice with
targeted disruption of COX-2, heterozygotes have appar-
ently normal COX-2 expression and function, indicating
that the observed renal abnormalities are due to the
absence of fetal COX-2. However, in these studies, it is
apparent that postnatal nephrogenesis also is severely
disrupted, as evidenced by the severe lesions noted in outer
cortical nephrons. Nephrogenesis occurs centrifugically,
and in the rodent, postnatal nephrogenesis continues for
the first 14 to 20 postnatal days. Therefore, the finding that
postnatal cortical COX-2 expression is highest in the first
few weeks of postnatal rats is consistent with a continuing
role in postnatal nephrogenesis.
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